Early detection of melanoma: a consensus report from the Australian Skin and Skin Cancer Research Centre Melanoma Screening Summit.
early detection
melanoma
prevention
screening
skin cancer
Journal
Australian and New Zealand journal of public health
ISSN: 1753-6405
Titre abrégé: Aust N Z J Public Health
Pays: United States
ID NLM: 9611095
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
01
09
2019
revised:
01
12
2019
accepted:
01
01
2020
pubmed:
20
3
2020
medline:
11
6
2020
entrez:
20
3
2020
Statut:
ppublish
Résumé
A Melanoma Screening Summit was held in Brisbane, Australia, to review evidence regarding current approaches for early detection of melanomas and explore new opportunities. Formal population-based melanoma screening is not carried out in Australia, but there is evidence of considerable opportunistic screening as well as early detection. Biopsy rates are rising and most melanomas are now diagnosed when in situ. Based on evidence review and expert opinion, the Summit attendees concluded that there is currently insufficient information in terms of comparative benefits, harms and costs to support change from opportunistic to systematic screening. Assessment of gains in precision and cost-effectiveness of integrating total body imaging, artificial intelligence algorithms and genetic risk information is required, as well as better understanding of clinical and molecular features of thin fatal melanomas. Research is needed to understand how to further optimise early detection of melanoma in Australia. Integrating risk-based population stratification and more precise diagnostic tests is likely to improve the balance of benefits and harms of opportunistic screening, pending assessment of cost-effectiveness. Implications for public health: The Summit Group identified that the personal and financial costs to the community of detecting and treating melanoma are rising, and this may be mitigated by developing and implementing a more systematic process for diagnosing melanoma.
Identifiants
pubmed: 32190955
doi: 10.1111/1753-6405.12972
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111-115Subventions
Organisme : NHMRC TRIP
ID : (115541)
Organisme : NHMRC Centre of Research Excellence in Melanoma
ID : (1135285)
Organisme : NHMRC Career Development
ID : (1147843)
Organisme : Cancer Institute NSW
ID : (15/CDF/1-14)
Informations de copyright
© 2020 The Authors.
Références
Australian Institute of Health and Welfare. Cancer in Australia [Internet]. Cancer series No.: 119. Canberra (AUST): AIHW; 2019 [cited 2019 Aug 12]. Available from: https://www.aihw.gov.au/getmedia/8c9fcf52-0055-41a0-96d9-f81b0feb98cf/aihw-can-123.pdf.aspx?inline=true
Australian Institute of Health and Welfare. Cancer in Adolescents and Young Adults in Australia [Internet]. Catalogue No.: 110. Canberra (AUST): AIHW; 2018 [cited 2019 Aug 19]. Available from: https://www.aihw.gov.au/getmedia/ed22109b-ab23-4273-8d23-7949a8922ea2/aihw-can-110.pdf.aspx?inline=true
Australian Institute of Health and Welfare. Skin Cancer in Australia [Internet]. Catalogue No.: 96. Canberra (AUST): AIHW; 2016 [cited 2019 Aug 12]. Available from: https://www.aihw.gov.au/getmedia/0368fb8b-10ef-4631-aa14-cb6d55043e4b/18197.pdf.aspx?inline=true
Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. J Invest Dermatol. 2015;135(4):1190-3.
Bell KJL, Mehta Y, Turner RM, Morton RL, Dieng M, Saw R, et al. Fear of new or recurrent melanoma after treatment for localised melanoma. Psychooncology. 2017;26(11):1784-91.
Aitken JF, Youlden DR, Baade PD, Soyer HP, Green AC, Smithers BM. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014. Int J Cancer. 2018;142(8):1528-35.
Curchin DJ, Harris VR, McCormack CJ, Smith SD. Changing trends in the incidence of invasive melanoma in Victoria, 1985-2015. Med J Aust. 2018;208(6):265-9.
Medicare Australia. Medicare - Item Reports 2019 [Internet]. Canberra (AUST): Australian Department of Human Services; 2019 [cited 2019 Aug 12]. Available from: http://medicarestatistics.humanservices.gov.au/statistics
Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Ebell M, Epling JW Jr, et al. Screening for skin cancer: US preventive services task force recommendation statement. JAMA. 2016;316(4):429-35.
Australian Department of Health. Population Based Screening Framework [Internet]. Canberra (AUST): Government of Australia; 2018 [cited 2019 Aug 12]. Available from: http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/16AE0B0524753EE9CA257CEE0000B5D7/$File/Population-Based-Screening-Framework.pdf
Marcus PM, Prorok PC, Miller AB, DeVoto EJ, Kramer BS. Conceptualizing overdiagnosis in cancer screening. J Natl Cancer Inst. 2015;107(4):djv014.
Dube C. Organized screening is better than opportunistic screening at decreasing the burden of colorectal cancer in the United States. Gastroenterology. 2018;155(5):1302-4.
Espinas JA, Aliste L, Fernandez E, Argimon JM, Tresserras R, Borras JM. Narrowing the equity gap: The impact of organized versus opportunistic cancer screening in Catalonia (Spain). J Med Screen. 2011;18(2):87-90.
Cancer Council Australia. Clinical Practice Guidelines for the Diagnosis and Management of Melanoma [Internet]. Sydney (AUST): CCA; 2019 [cited 2019 Aug 12]. Available from: https://wiki.cancer.org.au/australia/Guidelines:Melanoma
Hubner J, Eisemann N, Brunssen A, Katalinic A. Skin cancer screening in Germany: Review after ten years. Bundesgesundheitsblatt. 2018;61(12):1536-43.
Aitken JF, Janda M, Elwood M, Youl PH, Ring IT, Lowe JB. Clinical outcomes from skin screening clinics within a community-based melanoma screening program. J Am Acad Dermatol. 2006;54(1):105-14.
Aitken JF, Elwood M, Baade PD, Youl P, English D. Clinical whole-body skin examination reduces the incidence of thick melanomas. Int J Cancer. 2010;126(2):450-8.
Mar V, Roberts H, Wolfe R, English DR, Kelly JW. Nodular melanoma: A distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia. J Am Acad Dermatol. 2013;68(4):568-75.
Lattanzi M, Lee Y, Simpson D, Moran U, Darvishian F, Kim RH, et al. Primary melanoma histologic subtype: Impact on survival and response to therapy. J Natl Cancer Inst. 2019;111(2):180-8.
Pashayan N, Morris S, Gilbert FJ, Pharoah PDP. Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: A life-table model. JAMA Oncol. 2018;4(11):1504-10.
Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA. 2000;283(22):2975-8.
Burton RC, Armstrong BK. Recent incidence trends imply a nonmetastasizing form of invasive melanoma. Melanoma Res. 1994;4(2):107-13.
Pathirana T, Hayen A, Doust J, Glasziou P, Bell K. Lifetime risk of prostate cancer overdiagnosis in Australia: Quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach. BMJ Open. 2019;9(3):e022457.
Glasziou P, Jones M, Barratt A, Pathirana T, Bell K. The burden of cancer overdiagnosis in Australia. BMJ. 2019:http://dx.doi.org/10.1136/bmjebm-2019-POD.30.
Bell K. Melanoma Overdiagnosis in Australia. Melanoma Screening Summit. Brisbane (AUST): Translational Research Institute; 2019.
Doran CM, Ling R, Byrnes J, Crane M, Searles A, Perez D, et al. Estimating the economic costs of skin cancer in New South Wales, Australia. BMC Public Health. 2015;15:952.
Fransen M, Karahalios A, Sharma N, English DR, Giles GG, Sinclair RD. Non-melanoma skin cancer in Australia. Med J Aust. 2012;197(10):565-8.
Carter HE, Schofield DJ, Shrestha R. The productivity costs of premature mortality due to cancer in Australia: Evidence from a microsimulation model. PLoS One. 2016;11(12):e0167521.
Guy GP Jr, Ekwueme DU, Tangka FK, Richardson LC. Melanoma treatment costs: A systematic review of the literature, 1990-2011. Am J Prev Med. 2012;43(5):537-45.
Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: A systematic review. Eur J Cancer Prev. 2015;24(2):141-9.
The Royal Australian College of General Practitioners. Guidelines for Preventive Activities in General Practice [Internet]. 9th ed. East Melbourne (AUST): RACGP; 2018 [cited 2019 Aug 19]. Available from: https://www.racgp.org.au/FSDEDEV/media/documents/ClinicalResources/Guidelines/RedBook/Guidelines-for-preventive-activities-in-general-practice.pdf
Mann GJ, Cust A, Damian D, Fishburn P, Kelly J, Mar V, et al. Identification and Management of High-risk Individuals [Internet]. Sydney (AUST): Cancer Council of Australia; 2019 [cited 2019 Aug 12]. Available from: https://wiki.cancer.org.au/australia/Guidelines:Who_is_at_high_risk_of_new_primary_melanoma_and_how_should_risk_be_managed%3F
Vuong K, Armstrong BK, Weiderpass E, Lund E, Adami HO, Veierod MB, et al. Development and external validation of a melanoma risk prediction model based on self-assessed risk factors. JAMA Dermatol. 2016;152(8):889-96.
Vuong K, Armstrong BK, McGeechan K, Cust AE. Personalized melanoma risk assessments and tailored prevention advice: A pragmatic randomized controlled trial in Australian general practice. Fam Pract. 2019;36(2):237-46.
Olsen CM, Pandeya N, Thompson BS, Dusingize JC, Webb PM, Green AC, et al. Risk stratification for melanoma: Models derived and validated in a purpose-designed prospective cohort. J Natl Cancer Inst. 2018;110(10):1075-83.
Cust AE, Drummond M, Kanetsky PA, Goldstein AM, Barrett JH, MacGregor S, et al. Assessing the incremental contribution of common genomic variants to melanoma risk prediction in two population-based studies. J Invest Dermatol. 2018;138(12):2617-24.
Duffy DL, Lee KJ, Jagirdar K, Pflugfelder A, Stark MS, McMeniman EK, et al. High naevus count and MC1R red hair alleles contribute synergistically to increased melanoma risk. Br J Dermatol. 2019;181(5):1009-16.
Bafounta ML, Beauchet A, Aegerter P, Saiag P. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch Dermatol. 2001;137(10):1343-50.
Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 2002;3(3):159-65.
Menzies SW, Emery J, Staples M, Davies S, McAvoy B, Fletcher J, et al. Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: A sequential intervention trial. Br J Dermatol. 2009;161(6):1270-7.
Curiel-Lewandrowski C NR, Berry E, Leachman SA. Artificial intelligence approach in melanoma. In: Fisher DE BB, editor. Melanoma. New York (NY): Springer; 2019. p. 1-31.
Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.
Tschandl P, Codella N, Akay BN, Argenziano G, Braun RP, Cabo H, et al. Comparison of the accuracy of human readers versus machine-learning algorithms for pigmented skin lesion classification: An open, web-based, international, diagnostic study. Lancet Oncol. 2019;20(7):938-47.
Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE. State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin. 2016;66(6):460-80.
Koh U, Janda M, Aitken JF, Duffy DL, Menzies S, Sturm RA, et al. ‘Mind your Moles’ study: Protocol of a prospective cohort study of melanocytic naevi. BMJ Open. 2018;8(9):e025857.
Rayner JE, Laino AM, Nufer KL, Adams L, Raphael AP, Menzies SW, et al. Clinical perspective of 3D total body photography for early detection and screening of melanoma. Front Med. 2018;5:152.
Moloney FJ, Guitera P, Coates E, Haass NK, Ho K, Khoury R, et al. Detection of primary melanoma in individuals at extreme high risk: A prospective 5-year follow-up study. JAMA Dermatol. 2014;150(8):819-27.
Winkler JK, Fink C, Toberer F, Enk A, Deinlein T, Hofmann-Wellenhof R, et al. Association between surgical skin markings in dermoscopic images and diagnostic performance of a deep learning convolutional neural network for melanoma recognition. JAMA Dermatol. 2019 155(10):1135-1141.
Simon N, Simon R. Adaptive enrichment designs for clinical trials. Biostatistics. 2013;14(4):613-25.
Australian Skin and Skin Cancer Research Centre. ASSC Melanoma Screening Summit, 25 March 2019 [Internet]. Brisbane (AUST): Universtiy of Queensland ASSC; 2019 [cited 2019 Aug 19]. Available from: http://www.assc.org.au/
Watts CG, Cust AE, Menzies SW, Mann GJ, Morton RL. Cost-effectiveness of skin surveillance through a specialized clinic for patients at high risk of melanoma. J Clin Oncol. 2017;35(1):63-71.
Australian Government. Skin Cancer Screening [Internet]. Canberra (AUST): Australian Department of Health; 2019 [cited 2019 Jul 24]. Available from: http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/skin-cancer